José Federico
Díaz González
Catedrático de Universidad
Hospital Miguel Servet
Zaragoza, EspañaPublicaciones en colaboración con investigadores/as de Hospital Miguel Servet (10)
2024
-
Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis
European Journal of Clinical Investigation, Vol. 54, Núm. 2
2023
-
Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis
Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197
2021
2020
-
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
Scientific Reports, Vol. 10, Núm. 1
2019
-
Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry
Rheumatology International, Vol. 39, Núm. 3, pp. 509-515
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nature Communications, Vol. 10, Núm. 1
-
Objectives and methodology of BIOBADASER phase III
Reumatologia Clinica, Vol. 15, Núm. 4, pp. 229-236
2015
2011
-
Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis
Annals of the Rheumatic Diseases
-
No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis
Clinical and Experimental Rheumatology